Costs of human resources in delivering cancer chemotherapy and managing chemotherapy-induced neutropenia in community practice
- 1 May 2004
- journal article
- Published by Elsevier in Community Oncology
- Vol. 1 (1) , 23-28
- https://doi.org/10.1016/s1548-5315(11)70766-5
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Chemotherapy‐induced neutropeniaCancer, 2004
- Days of Prophylactic Filgrastim Use to Reduce Febrile Neutropenia in PatientsJournal of Managed Care Pharmacy, 2003
- Changing patient perceptions of the side effects of cancer chemotherapyCancer, 2002
- Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast CancerJournal of Clinical Oncology, 2002
- ‘More than just money’– widening the understanding of the costs involved in cancer careJournal of Advanced Nursing, 2001
- Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast CancerJNCI Journal of the National Cancer Institute, 1998
- Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement systemJournal of Pain and Symptom Management, 1997
- Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-upNew England Journal of Medicine, 1995
- Outpatient oncology settings: A variety of servicesSeminars in Oncology Nursing, 1994
- Nonmedical costs to patients and their families associated with outpatient chemotherapyCancer, 1984